Drug Profile

Alemtuzumab - Bayer/Sanofi/University of Cambridge

Alternative Names: Anti-CD52 monoclonal antibody; Campath; Campath-1H; LDP-03; Lemtrada; MabCampath; MabKampat; Remniq

Latest Information Update: 19 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Cambridge
Developer Bayer HealthCare Pharmaceuticals Inc.; Dana-Farber Cancer Institute; German CLL Study Group; Ohio State University Comprehensive Cancer Center; Sanofi; Sanofi Oncology; University of California; University of Cologne
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Chronic lymphocytic leukaemia; Multiple sclerosis
New Molecular Entity Yes

Marketed Chronic lymphocytic leukaemia; Multiple sclerosis
Phase II T-cell prolymphocytic leukaemia
Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
No development reported Diffuse large B cell lymphoma; Graft-versus-host disease; Lymphoma; Sezary syndrome; T-cell lymphoma
Discontinued Rheumatoid arthritis

20 Nov 2025 Sanofi terminates a phase III trial in Multiple sclerosis (In children, In adolescents) in Spain, Austria, Bulgaria, France, Greece, Portugal, Belgium, Netherlands, Italy, Poland, Russia, Turkey, United Kingdom (IV) due to recruitment challenges (NCT03368664)
29 Nov 2022 Phase-III development in Multiple sclerosis (In adolescents, In children) is ongoing in Belgium and Netherlands (IV) (NCT03368664)
13 Oct 2021 Updated efficacy and safety data from the phase III CARE-MS 1 follow-up TOPAZ trial in Multiple sclerosis presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com